

**TRITERPENE GLYCOSIDES FROM *Astragalus* AND THEIR GENINS.
LXXXVII. CHEMICAL TRANSFORMATION OF CYCLOARTANES.
IX. PARTIAL SYNTHESIS OF CYCLOASALGENIN**

I. M. Isaev, D. A. Iskenderov, and M. I. Isaev*


UDC 547.918:547.926

The natural cycloartane triterpenoid cycloasalgenin, which is 20R,24S-epoxycycloartan-3 β ,6 α ,25-triol-16-one, was partially synthesized in three steps starting from cyclosiversigenin. In addition to the desired product, its 17-epimer was synthesized. The analogous 17-epimer was also prepared from cycloasurgenin.

Keywords: *Astragalus*, Leguminosae, cycloartanes, cycloasalgenin, PMR, ^{13}C NMR, DEPT spectra.

In continuation of the chemical transformation of cycloartane triterpenoids [1], we synthesized partially cycloasalgenin (**6**), which was isolated from *Astragalus zahlbruckneri* Hand.-Mazz. (Leguminosae) in Turkey [2] and described without naming. For convenience, we called it cycloasalgenin. Cycloasalgenin is a 16-keto derivative of cyclosiversigenin. Therefore, we synthesized cycloasalgenin in three steps starting from cyclosiversigenin (**1**).

Cyclosiversigenin was acetylated by acetic anhydride in Py. The 3,6-diacetate (**2**), 6-monoacetate (**3**), and 3-monoacetate (**4**) of cyclosiversigenin, which were previously described [3, 4], were isolated from the reaction products.



Jones oxidation [5] was used to introduce the C-16 ketone into **2**. This produced **5**, the PMR spectrum of which exhibited at strong field (δ 0.80–1.19) resonances for seven methyls. This indicated that the side chain was retained. The resonance of H-17 in this same spectrum became a singlet at δ 2.85. This was consistent with oxidation of the 16 β -hydroxyl into a ketone. This was also consistent with the ^{13}C NMR spectrum of **5**, where the C-16 resonance appeared at δ 218.08.

The protecting groups were removed by alkaline hydrolysis of the diacetate of **5**. Ketones **6** and **7** were isolated from the hydrolysis products.

The PMR and ^{13}C NMR spectral data of **6** enabled it to be identified as cycloasalgenin [2]. A compound with an identical structure was obtained during elucidation of the structure of cycloastragenol (cyclosiversigenin) [6].

S. Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, fax: (99871) 120 64 75, e-mail: m_isaev@rambler.ru. Translated from *Khimiya Prirodnikh Soedinenii*, No. 3, pp. 345–348, May–June, 2010. Original article submitted November 2, 2009.

TABLE 1. Chemical Shifts of C Atoms in 1–9 (100 MHz, 125 MHz, CDCl₃, δ, ppm)

C atom	DEPT	1	2	3 (C ₅ D ₅ N)	4 (C ₅ D ₅ N)	5	6 (CDCl ₃)	6 (C ₅ D ₅ N)	7	8	9
1	CH ₂	32.45	31.78	32.31	31.96	31.70	31.36 ^a	31.37 ^a	32.20	31.91	31.85
2	CH ₂	31.80	25.93	31.15	27.09	25.98	30.52	30.55	31.02	35.65	35.84
3	CH(C)	78.70	79.97	77.18	80.82	79.76	78.58	78.15	78.54	217.68	217.15
4	C	41.85	40.49	41.98	40.87	40.53	41.84	42.37	41.83	50.52	50.50
5	CH	53.98	50.10	50.09	53.74	50.04	53.67	53.85	53.93	53.35	53.90
6	CH	69.43	70.71	71.18 ^a	68.00	70.30	68.85	67.88	69.04	69.58	69.92
7	CH ₂	38.30	33.28	33.73	38.65	33.46 ^a	38.13	38.65	37.98	38.02	38.10
8	CH	47.47	45.15	45.80	47.25	44.44	46.33	45.90	46.00	47.35	47.09
9	C	21.07	21.01	20.67	21.06	20.67	20.64	20.46	20.83	20.76	21.06
10	C	29.82	28.57	29.02	29.40	28.84	29.91	29.97	29.75	28.86	28.92
11	CH ₂	26.02	26.18	25.37	26.13	26.64	26.00	26.58	26.08	26.05	26.13
12	CH ₂	33.35	33.31	33.22	33.27	33.46 ^a	32.26	32.55	32.27	31.72	32.15
13	C	45.35	45.41	45.00	44.95	44.96	44.81	44.98	46.23	44.70	46.20
14	C	46.35	46.27	46.00	46.06	42.50	42.43	42.43	42.16	42.36	42.10
15	CH ₂	46.87	46.18	46.39	46.69	51.04	51.43	51.28	51.32	51.80	51.59
16	CH(C)	73.72	73.64	73.30	73.38	218.08	218.71	218.69	217.38	218.90	218.81
17	CH	57.87	57.67	58.21	58.34	65.50	65.50	65.96	65.14	65.56	65.23
18	CH ₃	21.82	21.25	21.31	21.64	19.96	20.37	20.10	20.23	20.84	20.71
19	CH ₂	30.63	29.39	29.55	30.89	29.46	31.36 ^a	31.37 ^a	30.53	31.60	31.42
20	C	87.42	87.40	87.18	87.19	84.79	84.80	84.75	83.93	84.77	83.87
21	CH ₃	28.03	28.06	28.17	28.15	25.58	25.52 ^b	24.99	24.25	25.52	24.25
22	CH ₂	34.79	34.75	34.86	34.88	32.08	32.07	32.17	37.92	31.72 ^a	37.86
23	CH ₂	26.22	26.93	26.43	26.42	26.89	26.67	25.95	25.52	26.68	25.52
24	CH	81.76	81.71	81.62	81.67	82.50	82.37	82.58	88.30	82.27	88.35
25	C	72.13	72.10	71.18 ^a	71.22	71.03	71.21	70.81	70.57	71.39	70.57
26	CH ₃	26.80	26.85	27.13	27.09	26.84	25.52 ^b	26.31	28.36	28.36	28.27
27	CH ₃	28.16	26.83	28.55	28.51	25.45	28.36	28.17	28.28	25.48	28.17
28	CH ₃	20.40	20.08	19.97	20.17	19.72	19.92	19.49	19.87	20.22*	20.48
29	CH ₃	28.54	28.12	27.49	28.82	28.36	28.41	29.32	29.58	28.48	29.62
30	CH ₃	15.62	16.59	16.01	16.68	16.60	15.61	16.13	15.60	20.20*	20.14
3-OAc	C	–	171.22	–	170.63	171.17	–	–	–	–	–
	CH ₃	–	21.60	–	21.18	21.59	–	–	–	–	–
6-OAc	C	–	170.73	170.31	–	170.71	–	–	–	–	–
	CH ₃	–	22.17	21.81	–	22.11	–	–	–	–	–

Resonances denoted by the same letters overlap within columns.

*Assignment of resonances is ambiguous. Assignments of C-26 and C-27 resonances are also interchangeable.


PMR and ¹³C NMR spectra of **7** showed that the side chain, including the tetrahydrofuran ring, was retained. Also, the resonance for H-17 in the PMR spectrum experienced a high-field shift by 0.23 pm compared with **6** and was observed at δ 2.63.

The C-17 resonance in the ¹³C NMR spectrum of **7** also shifted to strong field by 0.36 ppm relative to its position in **6** and appeared at δ 65.14 (Table 1).

These data suggested that C-17 had opposite configurations in **6** and **7**, i.e., the configuration of C-17 in **7** was inverted. Such configuration inversion of C-17 occurred obviously through keto-enol tautomerism during alkaline hydrolysis. Consequently, the subject ketone was a side product, i.e., the 17-epimer of cycloasagenin, and had the structure 20*R*,24*S*-epoxy-17-*epi*-cycloartan-3β,6α,25-triol-16-one, which is depicted as structure **7**.

Because epimerization at C-17 was observed in the chemistry of cycloartane triterpenoids for the first time, we carried out epimerization of another 16-ketocycloartane, cycloadsurgenin (**8**) [4]. Treatment of **8** with methanolic NaOH under conditions identical to those for preparing **7** formed **9**. Comparison of the PMR and ¹³C NMR spectra of **7** and **9** showed that the tetrahydrofuran ring in the side chain was retained in **9** and that the side-chain structure was identical in the two compounds. This was consistent with electrospray-ionization mass spectra in positive- and negative-ion mode (MS-ESIPI and

MS-ESINI) of **9**, where quasimolecular ions with m/z 509.3 $[M + Na]^+$ and 485.1 $[M - H]^-$ were found. Therefore, **9** was 20*R*,24*S*-epoxy-17-*epi*-cycloartan-6 α ,25-diol-3,16-dione, i.e., 17-*epi*-cycloasurgenin.



8: H-17 α , **9**: H-17 β

The configuration inversion of C-17 was also evident in the chemical shifts of side-chain C atoms C-20–C-27.

EXPERIMENTAL

General comments have been published [7]. We used solvent systems $CHCl_3$:MeOH (30:1, 1; 100:1, 2; 90:1, 3; and 50:1, 4).

PMR and ^{13}C NMR spectra were taken in $CDCl_3$ on UNITYplus 400 (Varian) and INOVA 600 (Varian) spectrometers with HMDS and TMS internal standards. ^{13}C NMR spectra were obtained with full C–H decoupling and under DEPT conditions. Chemical shifts of C atoms are given relative to the resonance of the C atom in $CDCl_3$ (δ 77.360). Chemical shifts of C atoms in the ^{13}C NMR spectrum of cycloasurgenin in deuteropyridine are given relative to the resonance of the β -C atoms of deuteropyridine (δ 123.493 vs. TMS).

IR spectra were recorded in KBr disks on a Bio-Rad FT-IR Spectrometer 165.

Electrospray-ionization mass spectra in positive- and negative-ion mode (MS ESIP and MS ESINI) were obtained in a Waters Alliance 2690-ZQ4000 (LC/MS) spectrometer.

Cyclosiversigenin (1), $C_{30}H_{50}O_5$, mp 239–241°C (MeOH), was prepared as before [4].

PMR spectrum (400 MHz, $CDCl_3$, δ , ppm, J/Hz, 0 = HMDS): 0.31 and 0.45 (d, $^2J = 4.5$, 2H-19), 0.89, 0.90, 1.08, 1.16, 1.20, 1.20, 1.23 (s, $7 \times CH_3$), 2.27 (d, $^3J = 7.9$, H-17), 2.51 (q, $^3J_1 = ^3J_2 = ^2J = 11.6$, H-22), 3.24 (dd, $^3J_1 = 11$, $^3J_2 = 4.5$, H-3), 3.47 (td, $^3J_1 = ^3J_2 = 9.9$, $^3J_3 = 3.4$, H-6), 3.68 (t, $^3J_1 = ^3J_2 = 7.9$, H-24), 4.62 (td, $^3J_1 = ^3J_2 = 7.9$, $^3J_3 = 6.3$, H-16). Table 1 lists the ^{13}C NMR spectrum.

3,6-Diacetate (2), 6-Monoacetate (3), and 3-Monoacetate (4) of Cyclosiversigenin from 1. Cyclosiversigenin (1.005 g) was acetylated by acetic anhydride (2.5 mL) in anhydrous Py (5 mL) for 4.5 h at 18°C, after which the mixture was poured into icewater. The resulting precipitate was filtered off, washed with water, and dried. The product was chromatographed over a column using system 1 to afford **2** (550 mg), $C_{34}H_{54}O_7$, mp 234–236°C (MeOH).

PMR spectrum (400 MHz, $CDCl_3$, δ , ppm, J/Hz, 0 = HMDS): 0.29 and 0.55 (d, $^2J = 4.8$, 2H-19), 0.78, 0.89, 0.93, 1.09, 1.16, 1.18, 1.24 (s, $7 \times CH_3$), 1.70 (d, $^3J = 9.7$, H-5), 1.93 (s, CH_3COO on C-6), 1.99 (s, CH_3COO on C-3), 2.27 (d, $^3J = 7.9$, H-17), 2.51 (q, $^2J = ^3J_1 = ^3J_2 = 10$, H-22), 3.69 (t, $^3J_1 = ^3J_2 = 7.4$, H-24), 4.51 (dd, $^3J_1 = 11$, $^3J_2 = 4.6$, H-3), 4.62 (td, $^3J_1 = ^3J_2 = 7.9$, $^3J_3 = 6.3$, H-16), 4.69 (td, $^3J_1 = ^3J_2 = 9.2$, $^3J_3 = 4.5$, H-6). Table 1 lists the ^{13}C NMR spectrum.

Continued elution of the column by the same solvent system isolated amorphous **3** (130 mg), $C_{32}H_{52}O_6$.

PMR spectrum (400 MHz, C_5D_5N , δ , ppm, J/Hz, 0 = HMDS): 0.17 and 0.44 (d, $^2J = 4.5$, 2H-19), 0.85, 1.11, 1.17, 1.18, 1.24, 1.25, 1.46 (s, $7 \times CH_3$), 1.92 (s, CH_3COO), 2.40 (d, $^3J = 7.8$, H-17), 2.98 (q, $^2J = ^3J_1 = ^3J_2 = 10.6$, H-22), 3.46 (dd, $^3J_1 = 11.6$, $^3J_2 = 4.6$, H-3), 3.75 (dd, $^3J_1 = 8.9$, $^3J_2 = 5.4$, H-24), 4.90 (m, H-16), 4.94 (td, $^3J_1 = ^3J_2 = 9.3$, $^3J_3 = 4$, H-6). Table 1 lists the ^{13}C NMR spectrum.

Further elution of the column with the same solvent system isolated **4** (120 mg), $C_{32}H_{52}O_6$, mp 243–245°C (MeOH).

PMR spectrum (400 MHz, C₅D₅N, δ , ppm, J/Hz, 0 = HMDS): 0.18 and 0.44 (d, ²J = 4, 2H-19), 0.84, 1.13, 1.17, 1.19, 1.30, 1.46, 1.47 (s, 7×CH₃), 1.96 (s, CH₃COO), 2.40 (d, ³J = 7.8, H-17), 2.98 (q, ²J = ³J₁ = ³J₂ = 11, H-22), 3.59 (m, H-6), 3.76 (dd, ³J₁ = 8.9, ³J₂ = 5.5, H-24), 4.80 (dd, ³J₁ = 11.6, ³J₂ = 4.5, H-3), 4.89 (m, H-16). Table 1 lists the ¹³C NMR spectrum.

3 β ,6 α -Diacetoxy-20R,24S-epoxycycloartan-25-ol-16-one (5) from 2. Diacetate **2** (550 mg) in acetone (100 mL) at -8°C was treated with Jones reagent (0.5 mL) [5] and stirred for 30 min. The excess of oxidant was decomposed by adding to the mixture several milliliters of MeOH. The mixture was poured into water and extracted with CHCl₃. The CHCl₃ extract was washed with water and evaporated. The solid was chromatographed over a column with elution by system 2 to afford **5** (370 mg), C₃₄H₅₂O₇, mp 227–229°C (MeOH).

PMR spectrum (400 MHz, CDCl₃, δ , ppm, J/Hz, 0 = HMDS): 0.36 and 0.58 (d, ²J = 4.9, 2H-19), 0.80, 1.04, 1.08, 1.11, 1.13, 1.19 (s, 7×CH₃), 1.93, 2.00 (s, 2×CH₃COO), 2.85 (s, H-17), 3.67 (dd, ³J₁ = 8, ³J₂ = 5.7, H-24), 4.53 (dd, ³J₁ = 11.4, ³J₂ = 4.7, H-3), 4.67 (td, ³J₁ = ³J₂ = 8.9, ³J₃ = 4.4, H-6). Table 1 lists the ¹³C NMR spectrum.

20R,24S-Epoxycycloartan-3 β ,6 α ,25-triol-16-one (6) (cycloasalenin) and 20R,24S-Epoxy-17-*epi*-cycloartan-3 β ,6 α ,25-triol-16-one (7) from 5. Diacetate **5** (100 mg) was treated with NaOH in MeOH (20 mL, 0.1%), left for 7 d at room temperature, acidified by adding H₂SO₄, and poured into water. The products were extracted by EtOAc. The EtOAc extract was washed with water and evaporated. The solid was chromatographed over a column with elution by system 3 to afford **7** (24 mg), C₃₀H₄₈O₅.

PMR spectrum (400 MHz, CDCl₃, δ , ppm, J/Hz, 0 = HMDS): 0.37 and 0.49 (d, ²J = 4.5, 2H-19), 0.91, 1.03 (s, 2×CH₃), 1.049 (d, ⁴J = 0.8, CH₃-28), 1.09, 1.19, 1.20, 1.25 (s, 4×CH₃), 1.94 (d, ²J = 18, H-15 α), 2.07 (dq, ²J = 18, ⁴J = 0.8, H-15 β), 2.63 (s, H-17), 2.64 (td, ²J = ³J₁ = 11.8, ³J₂ = 8.4, H-22), 3.26 (dd, ³J₁ = 11.2, ³J₂ = 4.5, H-3), 3.50 (td, ³J₁ = ³J₂ = 9.4, ³J₃ = 4, H-6), 3.89 (dd, ³J₁ = 10.5, ³J₂ = 6, H-24). Table 1 lists the ¹³C NMR spectrum.

Continued elution of the column by the same solvent system isolated **6** (30 mg), C₃₀H₄₈O₅, mp 214–215°C (MeOH).

PMR spectrum (400 MHz, CDCl₃, δ , ppm, J/Hz, 0 = HMDS): 0.36 and 0.49 (d, ²J = 4.3, 2H-19), 0.91, 1.04, 1.09, 1.11, 1.13, 1.19, 1.21 (s, 7×CH₃), 1.34 (d, ³J = 9.3, H-5), 2.04 (s, 2H-15), 2.86 (s, H-17), 3.27 (dd, ³J₁ = 11, ³J₂ = 4.5, H-3), 3.49 (td, ³J₁ = ³J₂ = 9.5, ³J₃ = 4, H-6), 3.67 (dd, ³J₁ = 8.5, ³J₂ = 5.5, H-24).

Table 1 lists the ¹³C NMR spectrum.

PMR spectrum (400 MHz, C₅D₅N, δ , ppm, J/Hz, 0 = HMDS): 0.21 and 0.48 (d, ²J = 4.4, 2H-19), 0.94 (dd, ⁴J₁ = 0.9, ⁴J₂ = 0.7, CH₃-28), 1.08, 1.13, 1.16, 1.25, 1.36 (s, 5×CH₃), 1.61 (d, ³J = 9.4, H-5), 1.78 (s, CH₃-29), 1.96 (dq, ²J = 17.8, ⁴J = 0.7, H-15 α), 2.09 (dq, ²J = 17.8, ⁴J = 0.9, H-15 β), 2.95 (s, H-17), 3.55 (dd, ³J₁ = 11.5, ³J₂ = 4.7, H-3), 3.66 (td, ³J₁ = ³J₂ = 9.4, ³J₃ = 3.7, H-6), 3.73 (dd, ³J₁ = 8, ³J₂ = 5.8, H-24).

Table 1 lists the ¹³C NMR spectrum.

20R,24S-Epoxy-17-*epi*-cycloartan-6 α ,25-diol-3,16-dione (9) from 8. Cycloasurgenin (**8**, 30 mg) was dissolved in methanolic NaOH (10 mL, 0.1%), left at room temperature for 7 d, poured into water, and extracted with EtOAc. After the usual work up and evaporation of solvent, the solid was chromatographed over a column using system 4 to afford **9** (12 mg), C₃₀H₄₆O₅.

IR spectrum (KBr, ν_{\max} , cm⁻¹): 3445 (OH), 1735 (>C=O on C-16), 1703 (>C=O on C-3).

MS-ESIPI (*m/z*): 509.3 [M + Na]⁺; MS-ESINI (*m/z*): 485.1 [M - H]⁻.

PMR spectrum (600 MHz, CDCl₃, δ , ppm, J/Hz, 0 = TMS): 0.52 and 0.70 (d, ²J = 4.2, 2H-19), 1.04, 1.13, 1.16, 1.23, 1.26, 1.34, 1.37 (s, 7×CH₃), 2.71 (s, H-17), 3.56 (td, ³J₁ = ³J₂ = 9.6, ³J₃ = 2.4, H-6), 3.89 (dd, ³J₁ = 10.2, ³J₂ = 5.4, H-24).

Table 1 lists the ¹³C NMR spectrum.

Continued elution with the same solvent system isolated **8** (10 mg).

ACKNOWLEDGMENT

The work was supported financially by FPFI, AS, RU (Grant 68-08), the State Foundation for Basic Research of the RU (Grant FA-F3-T-044), and GNTP (Grant FA-A12-T-101).

REFERENCES

1. I. M. Isaev, M. A. Agzamova, and M. I. Isaev, *Khim. Prir. Soedin.*, 339 (2010) [preceding article].
2. I. Calis, H. A. Gazar, S. Piacente, and C. Pizza, *J. Nat. Prod.*, **64**, 1179 (2001).
3. M. I. Isaev, M. B. Gorovits, N. D. Abdullaev, M. R. Yagudaev, and N. K. Abubakirov, *Khim. Prir. Soedin.*, 572 (1981).
4. I. M. Isaev, D. A. Iskenderov, and M. I. Isaev, *Khim. Prir. Soedin.*, 591 (2008).
5. C. Djerassi, R. R. Engle, and A. Bowers, *J. Org. Chem.*, **21**, 1547 (1956).
6. I. Kitagawa, H. K. Wang, A. Takagi, M. Fuchida, I. Miura, and M. Yoshikawa, *Chem. Pharm. Bull.*, **31**, 689 (1983).
7. R. P. Mamedova, M. A. Agzamova, and M. I. Isaev, *Khim. Prir. Soedin.*, 453 (2001).